Analyst Conference Summaries

Biotechnology Investor Aids

Alnylam Pharmaceuticals
ALNY

conference date: August 6, 2019 @ 5:00 AM Pacific Time

Alnylam as a Strategic Investment by William Meyers [February 21, 2019 Seeking Alpha]

Alnylam: Fully Priced, But A Future Star by William Meyers [August 21, 2018 Seeking Alpha]

Alnylam Readouts Offer Catalysts for 2017-2018 [June 24, 2016 Seeking Alpha]
Why Alnylam Should Be a Big Mover in 2016 [December 8, 2015 at Seeking Alpha]

Analyst Conference Notes by William P. Meyers
2019
Alnylam
Q1 2019
Alnylam
Q2 2019
   
May 1, 2019 August 6, 2019    
2018
Alnylam
Q4 2018
May 3, 2018
August 2, 2018
Nov. 7, 2018
Feb. 7, 2019
2017
May 5, 2017
August 9, 2017
Nov. 7, 2017
Feb. 8, 2018
2016
05/02/2016
08/04/2016
11/02/2016
02/08/2017
2015
05/07/2014
08/06/2015
11/09/2015
02/11/2016

Is Alnylam in 2020 Worth $9 Billion Now? [April 28, 2015 at Seeking Alpha]

Alnylam Pharmaceuticals (ALNY) is a clinical-stage developer of RNAi based therapies.

Alnylam web site

I sold my remaining ALNY stock on October 9, 2017. I may buy again if the stock price or developments make it attractive, by my standards, again.

 

Search

More Analyst Conference Pages:

 AGEN
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 CELG
 EPZM
 GILD
 GLYC
 INCY
 INO
 ISRG
 MCHP
 MYL
 REGN
 SGEN
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN

   
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2018 William P. Meyers